SciClone Says New Probe Opened After Fresh SEC Subpoena

Company directors won plaudits for the acquisition of a Chinese drug maker in 2011 but the outcome has been less rosy than it may originally have seemed.

Unlock unlimited access to all Global Investigations Review content